(NASDAQ: RYTM) Rhythm Pharmaceuticals's forecast annual revenue growth rate of 54.07% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Rhythm Pharmaceuticals's revenue in 2026 is $239,918,000.On average, 19 Wall Street analysts forecast RYTM's revenue for 2026 to be $22,031,289,198, with the lowest RYTM revenue forecast at $20,201,889,380, and the highest RYTM revenue forecast at $24,319,932,404. On average, 19 Wall Street analysts forecast RYTM's revenue for 2027 to be $39,079,753,222, with the lowest RYTM revenue forecast at $31,038,518,566, and the highest RYTM revenue forecast at $46,702,367,221.
In 2028, RYTM is forecast to generate $61,579,925,099 in revenue, with the lowest revenue forecast at $45,545,652,243 and the highest revenue forecast at $84,068,392,122.